Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients

Sponsor
Axel Brandes
Study ID
NCT04885634
Phase
PHASE3
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide Injectable Product — DRUG
    Subcutaneous injection of Semaglutide 2.4 mg once weekly
  • Placebo — DRUG
    Subcutaneous injection of volume-matched placebo once weekly

Study Details

The purpose of this pilot study is to assess the feasibility of a double-blind, randomized placebo-controlled trial of semaglutide 2.4 mg subcutaneously once weekly on top of standard care compared to standard care alone.

Key Dates

Start date
Oct 31, 2022
Status verified
Nov 2023
Primary completion
Jan 31, 2024
Completion
Nov 30, 2024

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Intervention group
    Semaglutide 2.4 mg subcutaneously once weekly in addition to standard AF care with lifestyle and risk factor management focusing on cardiovascular risk reduction
  • Placebo Comparator: Control group
    Placebo treatment with volume-matched placebo s.c. once weekly in addition to standard AF care with lifestyle and risk factor management focusing on cardiovascular risk reduction

Primary Outcome Measure

Number of Participants to Complete Recruitment [ Time Frame: Up to 68 weeks, until end of treatment ]

Related Studies